Patent ID: 7341552

Claim:
A method of classifying a glioma comprising: (a) obtaining a primary glioma tumor sample; (b) measuring in cells of the tumor sample the mRNA or protein expression level of MAPKK1, HTF4, transducin β2, BMP2A, TrkB, DAP3, RAB3A, transcription elongation factor SII, integrin beta I, IGFBP2, NKEFB, HSP27, neuromodulin, and LIMK1; (c) comparing the mRNA or protein expression levels obtained in step (b) with the expression levels of the mRNAs or proteins in step (b) from at least a first known glioma cell type; and (d) classifying said tumor sample as glioblastome multiforme (GM) when the sample shows altered expression of IGFBP2, NKEPFB and one or more of HSP27, neuromodulin or LIMK1, anaplastic astrocytoma (AA) when the sample shows altered expression of MAPKK1 and one or both of BMP2A or HTF4, anaplastic oligodendroglioma (AO) when the sample shows altered expression of DAP3 and either TrkB and RAB3A, or transcription elongation factor II and integrin β1, or oligodendroglioma (OL) when the sample shows altered expression of transducin β2 based on the expression comparison in step (c).